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ABSTRACT
Objectives Bacterial vaginosis (BV) is associated with
increased risk for sexually transmitted infections (STIs)
and HIV acquisition. This study describes the
epidemiology of BV in a cohort of women at high risk
for STI/HIV in Uganda over 2 years of follow-up between
2008–2011.
Methods 1027 sex workers or bar workers were
enrolled and asked to attend 3-monthly follow-up visits.
Factors associated with prevalent BV were analysed
using multivariate random-effects logistic regression. The
effect of treatment on subsequent episodes of BV was
evaluated with survival analysis.
Results Prevalences of BV and HIV at enrolment were
56% (573/1027) and 37% (382/1027), respectively.
Overall, 905 (88%) women tested positive for BV at
least once in the study, over a median of four visits.
Younger age, a higher number of previous sexual
partners and current alcohol use were independently
associated with prevalent BV. BV was associated with
STIs, including HIV. Hormonal contraception and condom
use were protective against BV. Among 853 treated BV
cases, 72% tested positive again within 3 months. There
was no difference in time to subsequent BV diagnosis
between treated and untreated women.
Conclusions BV was highly prevalent and persistent in
this cohort despite treatment. More effective treatment
strategies are urgently needed.
INTRODUCTION
Bacterial vaginosis (BV) is a common vaginal condi-
tion among women in sub-Saharan Africa, with
prevalence ranging from 6% to 58%.1 BV is charac-
terised by a reduction in lactic acid-producing
lactobacilli and concurrent increase in anaerobic
bacteria. BV has been described as a dysbiosis, or a
microbial imbalance, and has been associated with
preterm delivery,2 pelvic inﬂammatory disease
(PID)3 and sexually transmitted infections
(STIs).1 4–6 Furthermore, BV increases viral replica-
tion and vaginal shedding of HIV-17 and herpes
simplex virus (HSV)-2,8 facilitating transmission of
these viruses.
BV manifests clinically as a thin, whitish, homo-
geneous vaginal discharge and the presence of an
amine odour.9 However, BV is often asymptomatic;
in a recent study in South Africa, 90% of BV cases
were asymptomatic.10 Current recommendations
are that symptomatic BV is treated with oral metro-
nidazole 400–500 mg twice a day for 5–7 days;11 12
however, in resource-limited settings, BV is often
treated according to WHO recommendations for
managing vaginal discharge syndrome (VDS) with
2 g of metronidazole in a single dose.13
Once treated, BV often recurs; treatment trials
report cure rates of 80–90%, but recurrence rates
of 43% within 3 months.14 However, few studies
have reported the recurrence of BV in sub-Saharan
Africa where BV prevalence is high. In a study
carried out among 35-year-old to 65-year-old
women in South Africa, 32% of women treated for
BV had recurrent BV within 12 months.15 More
research is needed to investigate the occurrence and
recurrence of BV in key populations for HIV
infection.
The high prevalence of BV with its numerous
adverse sequelae and high recurrence rates is of
increasing international concern, especially in set-
tings with high rates of STIs and HIV. Reducing
prevalence of BV has the potential to reduce acqui-
sition of related infections.
Our study aims to describe the epidemiology of
BV in a cohort of women at high risk for STI and
HIV infection in Kampala, Uganda. We describe
the prevalence of BV over a 24-month period,
behavioural and biological factors associated with
BV, and the effect of treatment on subsequent diag-
nosis of BV.
METHODS
Study design, setting and participants
The study methods have been described previ-
ously.16 In brief, the Good Health for Women
Project is an observational cohort of self-identiﬁed
sex workers and women working in bars and other
entertainment venues in southern Kampala. The
study offers free general and reproductive health-
care for participants and their children aged under
5 years. Participants were recruited between 2008
and 2009 and asked to attend follow-up every
3 months. Genital samples were systematically col-
lected for the ﬁrst 24 months of follow-up.
Participants were included in the study if they
were aged at least 18 years or considered a mature
minor, involved in high-risk sexual activity and
willing to participate in HIV counselling and
testing. Participants attended an enrolment
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interview and clinical examination. At each visit, data were col-
lected on socio-demographic factors, alcohol and drug use,
intravaginal practices, sexual behaviour, contraception, preg-
nancy and current symptoms. Blood samples were obtained at
every visit; genital sampling and a routine genital examination
were carried out at all visits except at months 15 and 21 due to
ﬁnancial constraints. Genital symptoms were recorded at every
visit, and participants with symptoms consistent with PID, VDS
or genital ulcer disease (GUD) were treated syndromically
according to the Ugandan Ministry of Health Clinical
Guidelines for STI management.17 Participants treated for VDS
and PID received 2 g of metronidazole in a single dose or
400 mg of metronidazole twice daily for 14 days, respectively.17
In accordance with guidelines, women with asymptomatic
laboratory-diagnosed BV were not treated. Women with
laboratory-diagnosed asymptomatic STIs were treated. All parti-
cipants with conﬁrmed HIV infection were referred to an HIV
care centre.
Laboratory testing
A vaginal swab was used to prepare a Gram-stained slide that
was examined for vaginal yeast and for BV using Nugent
score.18 A Nugent score of 0–3 indicated normal microbiota, 4–
6 indicated intermediate microbiota and 7–10 indicated BV.
Another vaginal swab was inoculated in an InPouch culture for
Trichomonas vaginalis and read daily for motile trichomonads
for 5 days or until positive. A cervical swab was used to test for
Neisseria gonorrhoeae and Chlamydia trachomatis using the
Roche Amplicor C. trachomatis/N. gonorrhoeae PCR test. A
single HIVAbbott Determine HIV-1/2 rapid test was performed
onsite at the GHWP laboratory. Negative results were given to
the participant immediately. Positive samples were sent to the
MRC/UVRI serology laboratory in Entebbe for conﬁrmation
using Vironostika Uniform II (plus O) and Murex HIV EIA tests
performed in parallel. Discordant or equivocal tests were
retested by western blot to resolve the status. HIV-negative par-
ticipants were routinely retested at subsequent visits. Syphilis
serology was assessed using a quantitative Biotec rapid plasma
reagin (RPR) test and the Treponema pallidum haemagglutin-
ation test (TPHA). Active syphilis was deﬁned if both RPR and
TPHA tests were positive, and an RPR titre of ≥1:8 was consid-
ered high-titre active syphilis. HSV-2 serology was performed
using the HSV Type 2-IgG Kalon ELISA.
Statistical methods
Analyses were performed using Stata/SE, V.13.1 (StataCorp,
College Station, Texas, USA). BV was considered as a binary
outcome: samples with Nugent score of 0–6 were considered
BV negative and samples with Nugent scores 7–10 were consid-
ered BV positive. We assessed trends in BV prevalence over the
follow-up using logistic regression with random effects to
account for within-woman correlation. ORs for trend (ORtrend)
were obtained to estimate the change in BV prevalence from
one 3-monthly follow-up visit to the next.
For the risk factor analysis, we examined factors associated
with prevalent BV throughout the study period using a
repeated-measures analysis (random-effects logistic regression).
p-Values were obtained using likelihood ratio tests. Incident HIV
and HSV-2 infections were deﬁned as a positive test after a pre-
viously negative test.
A multivariate logistic regression model was constructed using
a modiﬁed hierarchical framework19 based on the following
levels: (1) socio-demographic, (2) sexual and behavioural factors
and (3) biological factors. Level 1 factors associated with BV
(p<0.20) in the unadjusted model were included in an adjusted
regression model and retained as level 1 variables if they
remained independently associated with BV (p<0.10).
Behavioural variables associated with BV (p<0.20), plus the
retained level 1 variables, were then included in the multivariate
model and retained as level 2 variables if they remained inde-
pendently associated with BV after adjustment for the covariates
in the model (p<0.10). Associations with level 3 factors were
assessed in the same way.
We also examined the effects of treatment on subsequent BV
separately for previously untreated cases and cases treated with
metronidazole at the last visit. For this analysis, we adjusted for
all variables retained in the framework described above.
Lastly, to investigate the effect of treatment on time to next
BV episode, we used Cox regression analysis and restricted the
data to participants who were diagnosed with BV at the enrol-
ment visit. We compared participants who were untreated,
treated with 2 g of metronidazole and treated with 400 mg of
metronidazole for 14 days. A multivariate Cox regression model
adjusted for all variables retained in the framework described
above, and any reported genital symptoms. A Kaplan–Meier
curve was used to illustrate the time to next diagnosis by
treatment.
RESULTS
Characteristics of study population at enrolment
Of the 1214 women screened, 1027 (85%) were eligible, con-
sented and enrolled in the cohort. The median age of the
cohort was 26 years, and the majority (89.3%) were under
35 years. Over 90% had some level of education, although few
(10.3%) had completed higher than primary level. The majority
(63.9%) were separated or divorced and most had children. At
enrolment, 69% of women reported ﬁve or more partners in
the last month. Two-thirds of participants reported at least ﬁve
occasions of transactional sex in the past month. Most women
(60%) reported consistent use of condoms with clients in the
past month, but 5% reported never using them. At enrolment,
56% of participants were assessed as problem drinkers by the
CAGE questionnaire.
Most women (94%) reported vaginal cleansing in the past
three months. Over half used water and soap to cleanse (57%)
and 40% reported cleansing more than three times a day. Over
half (56%) reported intravaginal insertion at least once in the
past three months, mostly using herbs or other traditional sub-
stances but also aerated drinks (eg, Coca-Cola), gels and saliva.
Genital symptoms were common at enrolment (68%) and
included dysuria (11%), genital itching (36%) or burning (21%),
dyspareunia (22%), lower abdominal pain (30%), abnormal dis-
charge (40%) or ulcers/blisters (12%); 61%, 23% and 7% were
treated at enrolment for VDS, PID and GUD, respectively.
Prevalence of N. gonorrhoeae infection was 13%, C. trachomatis
was 9% and T. vaginalis was 17%. Seroprevalences of HSV-2
(80%) and HIV (37%) were high.
BV prevalence over time and untreated BV
Of the 1027 women enrolled in the study, 69% were retained in
follow-up at 24 months with a median of four visits per woman
(range 1–7), amounting to a total of 5801 total visits. Of these,
5568 (96%) had an available Nugent score result and were
included in the analyses. The per-visit BV prevalence was 57%,
and 88% of the entire cohort had at least one positive BV
result. Of the women who attended all seven clinical visits,
more than half (58%) of the participants had a positive BV
result for at least four of the seven visits. Of the 3184 visits with
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BV diagnosis, 2033 (64%) had no signs or symptoms corre-
sponding to a diagnosis of VDS or PID documented, and there-
fore, remained untreated in line with current guidelines.
However, of these untreated BV cases, about half (46%)
reported at least one genital symptom and were not strictly
asymptomatic.
Prevalence of BV at enrolment was 56%, and there was a
small increase over time (ORtrend=1.10; 95% CI 1.05 to 1.14
per 3-month period) (table 1). However, there was a decrease in
prevalence of BV with any genital symptoms and treated BV
over time (ORtrend=0.48; 95% CI 0.45 to 0.52, ORtrend=0.77;
95% CI 0.74 to 0.82, respectively). We carried out a sensitivity
analysis by restricting the data to the 584 participant samples
available at 24 months, but the prevalences and trends remained
unchanged (see online supplementary table S1).
Factors associated with prevalent BV
Associations of BV with socio-demographic factors are shown in
table 2. In adjusted analyses, risk of BV was higher for women
who were younger (adjusted p-trend=0.004) and had lower
levels of education (adjusted p-trend=0.01). BV was independ-
ently associated with behavioural factors including increasing
number of lifetime partners (adjusted p-trend<0.001), any
alcohol use in the past three months (aOR=1.30; 95% CI 1.09
to 1.56) and decreased reported use of condoms with paying
clients in the past month (adjusted p-trend<0.001).
BV was independently associated with biological factors after
adjusting for socio-demographic and behavioural factors. The
strongest positive association was observed for high-titre syphilis
(aOR=2.93; 95% CI 1.62 to 5.39). BV was also independently
associated with prevalent HIV (aOR=1.94; 95% CI 1.54 to
2.44) and HSV-2 infections (aOR=1.69; 95% CI 1.27 to 2.24),
low-titre syphilis (aOR=1.47; 95% CI 1.04 to 2.09) and
N. gonorrhoeae infection (aOR=1.30; 95% CI 1.00 to 1.70). In
contrast, participants with vaginal yeast had a strongly reduced
risk of BV (aOR=0.45; 95% CI 0.34 to 0.59). There was some
evidence that pregnancy and hormonal contraception were asso-
ciated with a reduced risk of BV, especially use of depot medrox-
yprogesterone acetate (DMPA) injections (aOR=0.66; 95% CI
0.50 to 0.86 vs no contraception).
Effect of BV treatment on subsequent BV
There was a strong association between BV and having been
diagnosed with BV at the previous 3-month visit, irrespective of
whether the participant had received treatment (table 3).
Women who had received treatment for their BV at a previous
3-month visit were four times more likely to test positive for BV
than those with no previous BV diagnosis (aOR=4.35; 95% CI
3.34 to 5.66). Among 853 treated BV cases, 72% tested positive
again within 3 months.
Among women diagnosed with BV at enrolment (N=527),
there was no difference in time to subsequent BV diagnosis
between no treatment versus treatment with 2 g of metronida-
zole in a single dose or 400 mg of metronidazole twice daily for
14 days (aHR: 0.87; 95% CI 0.70 to 1.07 and aHR: 1.02; 95%
CI 0.75 to 1.39, respectively). Kaplan–Meier survival curves for
next BV diagnosis are shown in ﬁgure 1. Of the women who
had a subsequent BVepisode, the overall median time to diagno-
sis was 99 days (range 57–796 days).
DISCUSSION
Our study showed a high prevalence of BV in a population at
high risk of HIV and STIs—at any one visit, over half the parti-
cipants tested were BV positive. In line with current manage-
ment guidelines, half of all BV cases were not treated; yet there
was no difference in time to a subsequent BV diagnosis between
treated and untreated women with BV even after controlling for
any genital symptoms. Given the known association of BV with
STI/HIV, the high prevalence of BV and poor effectiveness of
current treatment strategies pose a major public health problem
in this population.
High prevalences of BV among female sex workers have been
reported elsewhere in sub-Saharan Africa: 70% in South Africa
and 40% in Kenya.20 21 The strong association between BV and
prevalent bacterial and viral STIs is consistent with previous
studies.1 4–6 While our analysis could not ascertain the direction
of causation, the literature reports mechanisms for a causal rela-
tionship between BV and STI acquisition. Vaginal acidity has
been shown to inhibit acquisition of N. gonorrhoeae,
C. trachomatis, HSV-2 and HIV.22–25 During episodes of BV,
lactobacilli, lactic acid and vaginal acidity are diminished, poten-
tially increasing susceptibility to these infections. BV also
induces an innate immune response in which cytokines asso-
ciated with HIV acquisition are upregulated.26 In the classic
transmission dynamics model of STIs, BV inﬂuences the trans-
mission probability by increasing susceptibility to STIs.
Importantly, half the participants had BV for over half their
study visits, suggesting that a large proportion of participants
may have long periods with increased susceptibility to STIs
including HIV infection. In addition, BV also increases
Table 1 Prevalence trends in bacterial vaginosis (BV) diagnosis over seven visits among those with Nugent results at each visit in a cohort of
1027 women at high risk in Kampala, Uganda (2008–2011)
Enrolment 3 months 6 months 9 months 12 months 18 months 24 months
n=1027 n=886 n=792 n=777 n=759 n=743 n=584 ORtrend* p Value† Trend
Normal 354 (35%) 330 (37%) 308 (39%) 298 (36%) 301 (40%) 262 (35%) 202 (35%) 1.00 (0.97 to 1.04) 0.87 ↔
Intermediate 100 (10%) 73 (8%) 60 (8%) 49 (6%) 29 (4%) 27 (4%) 14 (2%) 0.79 (0.74 to 0.84) <0.001 ↓
BV 573 (56%) 483 (55%) 424 (54%) 450 (58%) 429 (57%) 454 (61%) 368 (63%) 1.07 (1.04 to 1.11) <0.001 ↑
BV treated with metronidazole‡ 400 (70%) 270 (56%) 177 (42%) 138 (31%) 103 (24%) 41 (9%) 22 (6%) 0.78 (0.75 to 0.82) <0.001 ↓
BV with any genital symptoms§ 402 (70%) 309 (64%) 243 (57%) 244 (54%) 227 (53%) 259 (48%) 159 (43%) 0.48 (0.45 to 0.52) <0.001 ↓
*OR for trend in BV prevalence from one 3-monthly follow-up visit to the next.
†Likelihood ratio (LR) test p values were used to examine whether the ORtrend were likely to be due to chance.
‡This is a subset of the BV cases; treatment includes any participants with the diagnosis of BV and who were treated with 2 g of metronidazole in a single dose or 400 mg of
metronidazole twice daily for 14 days at that visit.
§This is a subset of the BV cases; ‘any genital symptoms’ included dysuria, genital itching or burning, dyspareunia, lower abdominal pain, abnormal discharge or ulcers/blisters. Genital
itching or burning, dysuria and ulcers/blisters are not treated with metronidazole in the syndromic management algorithm.
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Table 2 Factors associated with bacterial vaginosis (BV) at all visits in a repeated-measures analysis of 1027 women at high risk in Kampala,
Uganda (2008–2011)
Visits with BV diagnosed/
number of visits (%)
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Total 3180/5569 (57.1%)
Socio-demographic factors (level 1)*
Age (years; n=5569) ptrend=0.008 ptrend=0.004
14–24 1249/2111 (59.2%) 1 1
25–34 1623/2836 (57.3%) 0.89 (0.70 to 1.13) 0.87 (0.69 to 1.11)
35+ 309/622 (49.7%) 0.56 (0.38 to 0.82) 0.54 (0.37 to 0.79)
Highest education (n=5569) ptrend=0.03 ptrend=0.01
Higher than primary level 305/585 (52.1%) 1 1
Primary school completed 1246/2223 (56.1%) 1.19 (0.80 to 1.75) 1.21 (0.82 to 1.80)
Primary school not completed 1352/2321 (58.3%) 1.31 (0.89 to 1.94) 1.37 (0.93 to 2.03)
Never attended school 278/440 (63.2%) 1.81 (1.06 to 3.10) 1.91 (1.12 to 3.26)
Regular partner (n=5566)† p=0.29 p=0.32
No 702/1273 (55.2%) 1 1
Yes 2478/4293 (57.7%) 1.10 (0.92 to 1.33) 1.09 (0.91 to 1.32)
Number of live births (n=5224)† ptrend=0.06 ptrend=0.52
None 140/202 (69.3%) 1 1
1–2 1570/2736 (57.4%) 0.62 (0.34 to 1.16) 0.66 (0.36 to 1.24)
3–4 959/1715 (55.9%) 0.56 (0.30 to 1.06) 0.67 (0.35 to 1.28)
≥5 309/571 (54.1%) 0.49 (0.24 to 0.99) 0.63 (0.30 to 1.33)
Sexual and behavioural factors (level 2)‡
Age of first sex (years; n=5357)† p=0.15 p=0.76
≤14 1128/1881 (60.0%) 1 1
15–16 1182/2067 (57.2%) 0.87 (0.66 to 1.13) 0.93 (0.72 to 1.22)
17–18 603/1140 (52.9%) 0.69 (0.50 to 0.94) 0.85 (0.62 to 1.18)
≥19 152/269 (56.5%) 0.87 (0.51 to 1.51) 1.04 (0.60 to 1.79)
Number of lifetime sexual partners (n=5569) ptrend<0.001 ptrend<0.001
<20 347/690 (50.3%) 1 1
20–50 428/841 (50.9%) 1.05 (0.69 to 1.61) 1.05 (0.69 to 1.60)
50+ 184/327 (56.3%) 1.37 (0.79 to 2.39) 1.39 (0.80 to 2.54)
Can’t remember 2222/3711 (59.9%) 1.73 (1.22 to 2.44) 1.79 (1.26 to 2.37)
Involvement in sex work (N=5564)† p=0.14 p=0.47
Only reports sex work for employment 1040/1719 (60.5%) 1 1
Reports sex work and other employment 1789/3183 (56.2%) 0.86 (0.71 to 1.05) 0.90 (0.75 to 1.09)
Reports no sex work 348/662 (56.2%) 0.78 (0.60 to 1.02) 1.01 (0.72 to 1.43)
Number of paying sex partners in the past month (N=5569) p=0.09 p=0.79
0–4 1005/1869 (53.8%) 1 1
5–49 1648/2806 (58.7%) 1.30 (1.01 to 1.67) 1.09 (0.83 to 1.43)
50+ or can’t remember 528/894 (59.1%) 1.31 (0.93 to 1.84) 1.01 (0.70 to 1.46)
Use of condoms with paying partners in the last month (N=5562)† p=0.002 ptrend<0.001
Never 221/350 (63.1%) 1 1
Sometimes 259/404 (64.1%) 0.99 (0.68 to 1.43) 0.99 (0.68 to 1.44)
Most of the time 764/1223 (62.5%) 0.90 (0.65 to 1.24) 0.86 (0.63 to 1.19)
Always 1374/2511 (54.7%) 0.70 (0.51 to 0.94) 0.68 (0.50 to 0.92)
Not applicable§ 560/1074 (52.1%) 0.65 (0.48 to 0.90) 0.68 (0.49 to 0.93)
Alcohol use in the last three months (N=5567)† p=0.002 p=0.004
No 882/1705 (51.7%) 1 1
Yes 2298/3862 (59.5%) 1.33 (1.11 to 1.59) 1.30 (1.09 to 1.56)
Illicit drug use in the last three months (N=5569) p=0.07 p=0.35
No 2406/4277 (56.3%) 1 1
Yes 775/1292 (60.0%) 1.20 (0.99 to 1.45) 1.10 (0.81 to 1.33)
Intravaginal cleansing in the last three months (N=5558)† p=0.29 p=0.28
No 183/334 (54.8%) 1 1
Yes, with water only 1312/2346 (55.9%) 0.96 (0.68 to 1.36) 0.92 (0.65 to 1.30)
Yes, with soap 1679/2878 (58.3%) 1.09 (1.03 to 2.02) 1.05 (0.75 to 2.58)
High-frequency cleansing in the last three months (N=5217)†,¶ p=0.60 p=0.37
No 2096/3636 (57.7%) 1 1
Yes 892/1581 (56.4%) 0.96 (0.81 to 1.13) 0.93 (0.78 to 1.10)
Continued
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transmissibility of some viral STIs;7 8 therefore, women with
multiple episodes of BV may have prolonged periods of
increased infectiousness.
A 7-day metronidazole oral regimen of 500 mg twice a day
has been shown to provide an initial cure in 80–90% of BV
cases (36); however, cure is seldom long term and recurrence is
common.15 14 In many resource-limited settings, women with
symptomatic BV are managed according to national guidelines
for the syndromic management of VDS and prescribed 2 g of
metronidazole in a single dose. Previous research has shown
that this is less efﬁcacious than a 7-day course,27 and that recur-
rence is more common than with longer regimens.28 Our study
suggested a risk of a subsequent diagnosis following treatment
of >70%. While some participants were treated with a 14-day
course of metronidazole as treatment for PID, the survival ana-
lysis showed no evidence of a difference in time to next BV
diagnosis between no treatment, a single 2 g dose or 14-day
course of metronidazole. For the latter treatment, non-
adherence must be considered as a possible reason for persistent
BV, especially in populations with high alcohol use.
Interestingly, while there was an increase in overall BV preva-
lence over 24 months, there was a reduction in BV treated with
metronidazole and a more modest reduction of BV with any
symptoms. This apparent paradox may be better understood
within an ecological model of vaginal microbiota in which anti-
biotic perturbation causes shifts in the microbiota. Indeed,
Table 2 Continued
Visits with BV diagnosed/
number of visits (%)
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Insertion of a substance in the last three months (N=5568)†,** p=0.11 p=0.02
No 2129/3660 (58.2%) 1 1
Yes 1052/1908 (55.1%) 0.88 (0.75 to 1.03) 0.82 (0.69 to 0.97)
Biological factors (level 3)††
Hormonal factors (contraception/pregnancy; N=5368)† p=0.01 p=0.02
No contraception 1419/2338 (60.7%) 1 1
Oral contraceptive pill 321/365 (56.8%) 0.83 (0.56 to 1.23) 0.81 (0.56 to 1.17)
Depot progesterone injection 675/1309 (51.8%) 0.63 (0.47 to 0.85) 0.66 (0.50 to 0.86)
Other‡‡ 557/955 (58.3%) 0.94 (0.68 to 1.30) 1.02 (0.75 to 1.38)
Pregnant 209/401 (52.1%) 0.61 (0.39 to 0.95) 0.73 (0.48 to 1.10)
Vaginal yeast (N=5567)† p<0.001 p<0.001
No 3012/5158 (58.4%) 1 1
Yes 168/409 (41.1%) 0.44 (0.34 to 0.58) 0.45 (0.34 to 0.59)
Trichomonas vaginalis (N=5565)† p=0.003 p=0.05
No 2728/4924 (55.4%) 1 1
Yes 450/641 (70.2%) 1.44 (1.14 to 1.84) 1.27 (1.00 to 1.70)
Neisseria gonorrhoeae (N=5502)† p=0.001 p=0.05
No 2799/5012 (55.9%) 1 1
Yes 350/490 (71.4%) 1.54 (1.19 to 1.99) 1.30 (1.00 to 1.70)
Chlamydia trachomatis (N=5543)† p=0.66 p=0.86
No 3010/5283 (57.0%) 1 1
Yes 160/260 (61.5%) 1.08 (0.77 to 1.52) 1.03 (0.73 to 1.46)
Syphilis (N=5527)† p<0.001 p=0.001
Negative 2404/4395 (54.7%) 1 1
Past syphilis (TPHA+/rpr−) 332/540 (61.5%) 1.40 (1.00 to 1.97) 1.17 (0.84 to 1.63)
Positive:low titre (TPHA+/rpr<8) 311/450 (69.1%) 2.02 (1.43 to 2.85) 1.47 (1.04 to 2.09)
Positive:high titre (TPHA+/rpr≥8) 111/142 (78.2%) 3.02 (1.71 to 5.34) 2.95 (1.62 to 5.39)
Current herpes simplex virus (HSV)-2 status (N=5555)† p<0.001 p=0.001
Negative 410/923 (44.4%) 1 1
Prevalent HSV 2743/4593 (59.7%) 2.23 (1.68 to 2.95) 1.69 (1.27 to 2.24)
Incident HSV§§ 23/39 (59.0%) 2.41 (1.07 to 5.40) 2.07 (0.88 to 4.84)
Current HIV status (N=5372)† p<0.001 p<0.001
Negative 1704/3355 (50.8%) 1 1
Prevalent HIV 1317/1986 (66.3%) 2.35 (1.89 to 2.95) 1.94 (1.54 to 2.44)
Incident HIV§§ 23/31 (74.2%) 3.88 (1.44 to 10.46) 2.69 (0.98 to 7.37)
*Adjusted for age and level of education.
†The difference from the number of visits (N=5569) is due to missing data.
‡BV at all visits adjusted for age, level of education, number of lifetime partners, frequency of condom use with clients, any use of alcohol and intravaginal insertion (n=1027,
observations=5561).
§Includes those who did not have a paying partner in the past month.
¶High-frequency cleansing defined as cleansing >3 times/day, restricted to visits with reported cleansing in the past three months.
**Insertion of any of herbs, washing powder, soda, gel/lotions/Vaseline, saliva, other substances into vagina.
††BV adjusted for age, level of education, number of lifetime partners, frequency of condom use with clients, any use of alcohol, intravaginal insertion, HIV, HSV-2, vaginal yeast,
T. vaginalis, N. gonorrhoeae, syphilis, hormonal contraception/pregnancy (N=1006, observations=4937).
‡‡Includes condoms, withdrawal methods, natural methods, traditional methods.
§§First diagnosed at this visit.
TPHA, Treponema pallidum haemagglutination test.
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different BV-associated bacterial species and their metabolites
have been shown to be associated with different clinical cri-
teria;29 for example, Atopobium vaginae is associated with
vaginal discharge and high pH, but not with an amine odour,
while Prevotella bivia is associated with an amine odour and
high pH, but not vaginal discharge. Therefore, treatment may
clear bacteria responsible for some types of symptoms, while
other types may remain and overgrow, causing a modiﬁed clin-
ical presentation or asymptomatic recurrent infection. More
research is needed to understand the dynamics of the vaginal
microbiota in this population in relation to treatment and
recurrence.
Our study suggests that hormonal contraception may be pro-
tective against BV, and this has also been shown elsewhere.30
Therefore, the promotion of hormonal contraception may also
be a potentially effective intervention to prevent BV in this
population. Lactobacilli metabolise glycogen from oestrogenised
epithelial cells; therefore, exogenous oestrogen in combined
contraceptives is thought to promote Lactobacillus colonisation.
In progesterone-only contraceptives, such as DMPA, it has been
theorised that the reduction in menstruation is protective
against BV. However, caution is needed in view of recent
meta-analysis showing increased risk of HIV associated with
DMPA.31
Strengths of our study included its longitudinal design and
the high retention rate in a high-risk population, providing a
rich data source to examine multiple correlates of BV over time,
although some bias due to losses to follow-up cannot be
excluded. There were some further limitations to our study.
Shifts in vaginal microbiota can be rapid, causing short episodes
of BV and fast response to treatment.32 BV testing in this study
was not designed to detect treatment success and was limited to
3-month and 6-month intervals; however, the rates of repeat
positive tests were similar to 3-month recurrence rates observed
in other treatment trials that included more intensive BV
testing.14 Risk factors related to behaviours or infections of
male partners were not measured in our study (eg, circumci-
sion), and there may have been residual confounding if there
were unmeasured or inaccurately measured risk behaviours.
In summary, for populations with high prevalence of BV and
high HIV and STI incidence, more effective treatment strategies
for BV are urgently needed. The development of innovative
treatment strategies that effectively treat initial episodes of BV
and prevent rapid recurrence should be a public health priority.
Additionally, the potential role of hormonal contraceptives in
the prevention of BV should be examined. Better treatments are
required before carrying out trials to evaluate the impact of
treatment of BV on the prevention of STIs, HIV or poor birth
outcomes.
Key messages
▸ We found a very high prevalence (56%) of bacterial
vaginosis (BV) among women who are at high risk for HIV
and sexually transmitted infections (STIs).
▸ Of the women who were treated for BV, 72% had a second
episode by 3 months.
▸ In line with current management guidelines, half of all BV
cases were not treated; yet there was no difference in time
to a subsequent BV diagnosis between treated and
untreated women with BV.
▸ This is the highest rate of recurrent diagnosis reported to
date and highlights the need to focus efforts on improved
treatment of BV for the prevention of STIs and HIV in
populations of high risk.
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diagnosed with BV at the enrolment visit in a cohort of 1027 women
at high risk in Kampala, Uganda (2008–2011). This is over a 24-month
period and stratiﬁed by treatment at the enrolment visit. The initial ﬂat
line reﬂects the intervals for scheduled clinic visits.
Table 3 The association of bacterial vaginosis (BV) with treated or untreated BV at the visit 3 months prior at all visits in a repeated measures
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n/N (%)
Unadjusted
odds ratio (95% CI)
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6 Francis SC, et al. Sex Transm Infect 2015;0:1–7. doi:10.1136/sextrans-2015-052160
Epidemiology
group.bmj.com on October 8, 2015 - Published by http://sti.bmj.com/Downloaded from 
data teams of the MRC/UVRI Unit in Entebbe and Women at Work International
Uganda.
Contributors SCF and CL contributed equally. HG, RJH, JV, HAW, CL and SCF
contributed to the conception and design of the work. JV, JB, YM, PH and SN
contributed to the acquisition of the data for the work. SCF, CL and HAW performed
the statistical analysis. CL and SCF drafted the manuscript. All authors contributed
to revising it critically for important intellectual contact and approved of the ﬁnal
version.
Funding Financial support for this study was provided by the European and
Developing Countries Clinical Trials Partnership (project code: CT_ct_05_32070_002)
and from the UK Medical Research Council (MRC) and the Department for
International Development (DFID) through a MRC/DFID concordat (Core Unit fund
88496) with HG and JV receiving salary support. Additionally, SCF (G1002369), HAW,
RJH (G0700837) received salary support through MRC/DFID. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing interests None declared.
Ethics approval Science and Ethics Committee of the Ugandan Virus Research
Institute, the Ugandan National Committee for Science and Technology and the
Ethics Committee of the London School of Hygiene and Tropical Medicine committee
number 5198.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All authors have access to the original cohort data,
database and study results. Further access to unpublished data is available upon
request.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1 Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis,
and HIV infection in women: individual participant data meta-analysis. PLoS Med
2011;8:e1000416.
2 Leitich H, Bodneradler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for
preterm delivery: a meta-analysis. Am J Obstet Gynecol 2003;189:139–47.
3 Hillier SL, Kiviat NB, Hawes SE, et al. Role of bacterial vaginosis-associated
microorganisms in endometritis. Am J Obstet Gynecol 1996;175:435–41.
4 Cherpes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes
simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis
2003;37:319–25.
5 Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor
of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis
2003;36:663–8.
6 Balkus JE, Richardson BA, Rabe LK, et al. Bacterial vaginosis and the risk of
trichomonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis
2014;41:123–8.
7 Cu-Uvin S, Hogan JW, Caliendo AM, et al. Association between bacterial vaginosis
and expression of human immunodeﬁciency virus type 1 RNA in the female genital
tract. Clin Infect Dis 2001;33:894–6.
8 Cherpes TL, Melan MA, Kant JA, et al. Genital tract shedding of herpes simplex
virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and
vaginal group B Streptococcus colonization. Clin Infect Dis 2005;40:1422–8.
9 Amsel R, Totten PA, Spiegel CA, et al. Nonspeciﬁc vaginitis. Diagnostic criteria and
microbial and epidemiologic associations. Am J Med 1983;74:14–22. http://www.
ncbi.nlm.nih.gov/pubmed/6600371 (accessed 22 Aug 2011).
10 Mlisana K, Naicker N, Werner L, et al. Symptomatic vaginal discharge is a poor
predictor of sexually transmitted infections and genital tract inﬂammation in
high-risk women in South Africa. J Infect Dis 2012;206:6–14.
11 Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010.
MMWR Recomm Rep 2010;59:1–110. http://www.ncbi.nlm.nih.gov/pubmed/
21160459 (accessed 3 Jan 2014).
12 Sherrard J, Donders G, White D, et al. European (IUSTI/WHO) guideline on the
management of vaginal discharge, 2011. Int J STD AIDS 2011;22:421–9.
13 World Health Organization. Guidelines for the management of sexually transmitted
infections. Geneva: WHO, 2003.
14 Bradshaw CS, Morton AN, Hocking JS, et al. High recurrence rates of bacterial
vaginosis over the course of 12months after oral metronidazole therapy and factors
associated with recurrence. J Infect Dis 2006;193:1478–86.
15 Myer L, Kuhn L, Denny L, et al. Recurrence of symptomatic bacterial vaginosis
12months after oral metronidazole therapy in HIV-positive and -negative women.
J Infect Dis 2006;194:1797–9.
16 Vandepitte J, Weiss HA, Bukenya J, et al. Alcohol use, mycoplasma genitalium, and
other STIs associated With HIV incidence among women at high risk in Kampala,
Uganda. J Acquir Immune Deﬁc Syndr 2013;62:119–26.
17 Ministry of Health. Uganda clinical guidelines: National Guidelines on Management
of Common Conditions. Kampala, Uganda, 2010.
18 Nugent RP, Krohn MA, Hillier SL, et al. Reliability of diagnosing bacterial vaginosis
is improved by a standardized method of gram stain interpretation. J Clin Microbiol
1991;29:297–301. http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=269757&tool=pmcentrez&rendertype=abstract
19 Victora CG, Huttly SR, Fuchs SC, et al. The role of conceptual frameworks in
epidemiological analysis: a hierarchical approach. Int J Epidemiol 1997;26:224–7.
20 Ramjee G, Karim SS, Sturm AW. Sexually transmitted infections among sex workers
in KwaZulu-Natal, South Africa. Sex Transm Dis 1998;25:346–9. http://www.ncbi.
nlm.nih.gov/pubmed/9713913 (accessed 8 Nov 2011).
21 Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial ﬂora,
and risk of human immunodeﬁciency virus type 1 and sexually transmitted disease
acquisition. J Infect Dis 1999;180:1863–8.
22 Graver MA, Wade JJ. The role of acidiﬁcation in the inhibition of Neisseria
gonorrhoeae by vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol
Antimicrob 2011;10:8.
23 Gong Z, Luna Y, Yu P, et al. Lactobacilli inactivate Chlamydia trachomatis through
lactic acid but not H2O2. PLoS ONE 2014;9:e107758.
24 Conti C, Malacrino C, Mastromarino P. Inhibition of herpes simplex virus type 2 by
vaginal lactobacilli. J Physiol Pharmacol 2009;60(Suppl 6):19–26.
25 Lai SK, Hida K, Shukair S, et al. Human immunodeﬁciency virus type 1 is trapped by
acidic but not by neutralized human cervicovaginal mucus. J Virol
2009;83:11196–200.
26 Mitchell C, Marrazzo J. Bacterial Vaginosis and the Cervicovaginal Immune
Response. Am J Reprod Immunol 2014;71:555–63.
27 Swedberg J, Steiner JF, Deiss F, et al. Comparison of single-dose vs one-week
course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985;254:
1046–9.http://www.ncbi.nlm.nih.gov/pubmed/3894707 (accessed 7 Mar 2014).
28 Koumans EH, Markowitz LE, Hogan V. Indications for therapy and treatment
recommendations for bacterial vaginosis in nonpregnant and pregnant women:
a synthesis of data. Clin Infect Dis 2002;35:S152–72.
29 Srinivasan S, Hoffman NG, Morgan MT, et al. Bacterial communities in women with
bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of
microbiota to clinical criteria. PLoS ONE 2012;7:e37818.
30 Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a
reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS ONE
2013;8:e73055.
31 Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV
acquisition: an individual participant data meta-analysis. PLoS Medicine 2015;21(1).
doi:10.1371/journal.pmed.1001778.
32 Srinivasan S, Liu C, Mitchell CM, et al. Temporal variability of human vaginal
bacteria and relationship with bacterial vaginosis. PLoS ONE 2010;5:e10197.
Francis SC, et al. Sex Transm Infect 2015;0:1–7. doi:10.1136/sextrans-2015-052160 7
Epidemiology
group.bmj.com on October 8, 2015 - Published by http://sti.bmj.com/Downloaded from 
diagnosis despite treatment
risk for HIV in Uganda: high rate of recurrent 
Bacterial vaginosis among women at high
Helen A Weiss and Heiner Grosskurth
Yunia Mayanja, Susan Nakubulwa, Peter Hughes, Richard J Hayes, 
Suzanna C Francis, Clare Looker, Judith Vandepitte, Justine Bukenya,
 published online August 7, 2015Sex Transm Infect 
 http://sti.bmj.com/content/early/2015/08/07/sextrans-2015-052160
Updated information and services can be found at: 
These include:
Material
Supplementary
 C1.html
http://sti.bmj.com/content/suppl/2015/08/07/sextrans-2015-052160.D
Supplementary material can be found at: 
References
 #BIBL
http://sti.bmj.com/content/early/2015/08/07/sextrans-2015-052160
This article cites 29 articles, 13 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (463)Sex workers
 (1316)Reproductive medicine
 (155)Drugs: obstetrics and gynaecology
 (242)Contraception
 (737)Condoms
 (447)Vulvovaginal disorders
 (2425)HIV/AIDS
 (2425)HIV infections
 (2425)HIV / AIDS
 (3077)Drugs: infectious diseases
 (191)Open access
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 8, 2015 - Published by http://sti.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 8, 2015 - Published by http://sti.bmj.com/Downloaded from 
